|
US4172896A
(en)
|
1978-06-05 |
1979-10-30 |
Dainippon Pharmaceutical Co., Ltd. |
Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
|
|
GB9217295D0
(en)
|
1992-08-14 |
1992-09-30 |
Wellcome Found |
Controlled released tablets
|
|
US5358970A
(en)
|
1993-08-12 |
1994-10-25 |
Burroughs Wellcome Co. |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
|
US5541231A
(en)
|
1993-07-30 |
1996-07-30 |
Glaxo Wellcome Inc. |
Stabilized Pharmaceutical
|
|
GB9315856D0
(en)
|
1993-07-30 |
1993-09-15 |
Wellcome Found |
Stabilized pharmaceutical
|
|
DE69531543T2
(de)
|
1994-06-17 |
2004-06-24 |
F. Hoffmann-La Roche Ag |
N,n'-bis(chinolin-4-yl)-diamin derivate, deren herstellung und deren verwendung als antimalaria-mittel
|
|
AU4515696A
(en)
|
1994-12-12 |
1996-07-03 |
Merck & Co., Inc. |
Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
|
|
NZ325248A
(en)
|
1995-12-23 |
1999-09-29 |
Pfizer Res & Dev |
Quinoline and quinazoline compounds useful in therapy
|
|
SE9603285D0
(sv)
|
1996-09-10 |
1996-09-10 |
Astra Ab |
New compounds
|
|
US5874438A
(en)
|
1996-10-11 |
1999-02-23 |
Bayer Aktiengesellschaft |
2,2'-bridged bis-2,4-diaminoquinazolines
|
|
DK0999825T3
(da)
|
1997-07-29 |
2004-02-09 |
Alcon Lab Inc |
Oftalmiske sammensætninger indeholdende galactomannanpolymerer og borater
|
|
US6110973A
(en)
|
1998-01-29 |
2000-08-29 |
Sepracor |
Methods for treating obesity and weight gain using optically pure (-)-bupropion
|
|
US8889112B2
(en)
|
1999-09-16 |
2014-11-18 |
Ocularis Pharma, Llc |
Ophthalmic formulations including selective alpha 1 antagonists
|
|
US20040138284A1
(en)
|
2000-02-11 |
2004-07-15 |
Matthias Wiesner |
Indol-3-yl derivatives
|
|
GB0014022D0
(en)
|
2000-06-08 |
2000-08-02 |
Novartis Ag |
Organic compounds
|
|
WO2002020500A2
(en)
|
2000-09-01 |
2002-03-14 |
Icos Corporation |
Materials and methods to potentiate cancer treatment
|
|
EP1217000A1
(en)
|
2000-12-23 |
2002-06-26 |
Aventis Pharma Deutschland GmbH |
Inhibitors of factor Xa and factor VIIa
|
|
CA2461202C
(en)
|
2001-09-21 |
2011-07-12 |
Donald Pinto |
Lactam-containing compounds and derivatives thereof as factor xa inhibitors
|
|
AU2003209321A1
(en)
|
2002-01-18 |
2003-07-30 |
Pharmacia Corporation |
Substituted pyridazinones as inhibitors of p38
|
|
US7312214B2
(en)
|
2002-05-10 |
2007-12-25 |
Bristol-Myers Squibb Company |
1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors
|
|
US20040087590A1
(en)
|
2002-08-23 |
2004-05-06 |
University Of Connecticut |
Novel biphenyl and biphenyl-like cannabinoids
|
|
AU2003286711A1
(en)
|
2002-10-25 |
2004-05-13 |
Vertex Pharmaceuticals Incorporated |
Indazolinone compositions useful as kinase inhibitors
|
|
AU2003299790A1
(en)
|
2002-12-20 |
2004-07-22 |
Bayer Pharmaceuticals Corporation |
Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
|
|
US20050197350A1
(en)
|
2003-03-31 |
2005-09-08 |
Taisho Pharmaceutical Co., Ltd. |
Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
|
|
KR20050114283A
(ko)
|
2003-04-22 |
2005-12-05 |
아바니르 파마슈티컬스 |
고콜레스테롤혈증을 치료하기 위한 역 콜레스테롤 수송의매개제
|
|
US6933289B2
(en)
|
2003-07-01 |
2005-08-23 |
Allergan, Inc. |
Inhibition of irritating side effects associated with use of a topical ophthalmic medication
|
|
CA2534484A1
(en)
|
2003-08-07 |
2005-02-17 |
Allergan, Inc. |
Compositions for delivery of therapeutics into the eyes and methods for making and using same
|
|
US20050059744A1
(en)
|
2003-09-12 |
2005-03-17 |
Allergan, Inc. |
Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
|
|
MXJL06000069A
(es)
*
|
2004-06-09 |
2007-04-10 |
Avanir Pharmaceuticals |
Derivados heterociclicos para el tratamiento de hiperlipidemia y enfermedades relacionadas.
|
|
US7829712B2
(en)
|
2004-09-20 |
2010-11-09 |
Xenon Pharmaceuticals Inc. |
Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
|
|
US20080090863A1
(en)
|
2004-09-30 |
2008-04-17 |
Taisho Pharmaceutical Co., Ltd. |
Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor
|
|
US7381732B2
(en)
|
2004-10-26 |
2008-06-03 |
Bristol-Myers Squibb Company |
Pyrazolobenzamides and derivatives as factor Xa inhibitors
|
|
EP1814856A1
(en)
|
2004-11-12 |
2007-08-08 |
Galapagos N.V. |
Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
|
|
GB0428082D0
(en)
|
2004-12-22 |
2005-01-26 |
Welcome Trust The Ltd |
Therapeutic compounds
|
|
JP2008531596A
(ja)
|
2005-02-25 |
2008-08-14 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
Ｈｃｖ感染を治療または予防するのに有用なベンゾイソチアゾール
|
|
CA2603830A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Pharmacia & Upjohn Co Llc |
PYRIDINE [2,3-B] PYRAZINONES
|
|
JP5118029B2
(ja)
|
2005-06-14 |
2013-01-16 |
タイゲン バイオテクノロジー カンパニー，リミテッド |
ピリミジン化合物
|
|
US20070203236A1
(en)
|
2006-01-11 |
2007-08-30 |
Smith Jeffrey W |
Novel antagonists of the human fatty acid synthase thioesterase
|
|
JP2007291087A
(ja)
|
2006-03-29 |
2007-11-08 |
Taisho Pharmaceut Co Ltd |
ピリジン誘導体及びその使用に関連する治療法
|
|
UA95644C2
(ru)
|
2006-07-25 |
2011-08-25 |
Сефалон, Инк. |
Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
|
|
US20080255155A1
(en)
|
2006-10-18 |
2008-10-16 |
Stephane Raeppel |
Kinase inhibitors and uses thereof
|
|
WO2008061796A2
(en)
|
2006-11-24 |
2008-05-29 |
Ac Immune Sa |
Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
|
|
KR101442288B1
(ko)
|
2006-12-13 |
2014-09-19 |
지보당 네덜란드 서비시즈 비.브이. |
카복실산과 퓨린, 피리미딘, 뉴클레오사이드 또는 뉴클레오타이드의 향미 조절 유도체
|
|
EP2205639B1
(en)
*
|
2007-10-26 |
2015-12-23 |
Merck Sharp & Dohme Corp. |
Anti-pcsk9 and methods for treating lipid and cholesterol disorders
|
|
US7803809B2
(en)
|
2008-11-12 |
2010-09-28 |
Amgen Inc. |
Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
|
|
CA2726588C
(en)
|
2008-06-03 |
2019-04-16 |
Karl Kossen |
Compounds and methods for treating inflammatory and fibrotic disorders
|
|
WO2010048149A2
(en)
|
2008-10-20 |
2010-04-29 |
Kalypsys, Inc. |
Heterocyclic modulators of gpr119 for treatment of disease
|
|
NZ624963A
(en)
|
2009-04-29 |
2016-07-29 |
Amarin Pharmaceuticals Ie Ltd |
Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
|
|
WO2011008931A2
(en)
|
2009-07-15 |
2011-01-20 |
Cystic Fibrosis Foundation Therapeutics, Inc. |
Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
|
|
MX2012001504A
(es)
|
2009-08-05 |
2012-06-01 |
Versitech Ltd |
Compuestos antivirales y metodos para elaborarlos y usarlos.
|
|
AU2011253058A1
(en)
|
2010-05-13 |
2012-12-06 |
Amgen Inc. |
Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
|
|
WO2011147199A1
(en)
|
2010-05-28 |
2011-12-01 |
Versitech Limited |
Compounds and methods for treating viral infections
|
|
CN102933559B
(zh)
|
2010-06-04 |
2016-01-27 |
兴和株式会社 |
光学活性二苄胺衍生物及其制备方法
|
|
JP5925771B2
(ja)
|
2010-06-24 |
2016-05-25 |
トラスティーズ オブ タフツ カレッジ |
ナイアシン模倣体、およびその使用方法
|
|
WO2011163612A1
(en)
|
2010-06-24 |
2011-12-29 |
Trustees Of Tufts College |
Niacin mimetics, and methods of use thereof
|
|
EP2592933B1
(en)
|
2010-07-16 |
2017-04-05 |
Anderson Gaweco |
Mif inhibitors and their uses
|
|
WO2012016133A2
(en)
|
2010-07-29 |
2012-02-02 |
President And Fellows Of Harvard College |
Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
|
|
WO2012088438A1
(en)
|
2010-12-22 |
2012-06-28 |
Eutropics Pharmaceuticals, Inc. |
Compositions and methods useful for treating diseases
|
|
JP2014506878A
(ja)
|
2011-01-28 |
2014-03-20 |
ノバルティス アーゲー |
Ｃｄｋ９阻害剤としての置換ビ−ヘテロアリール化合物およびそれらの使用
|
|
US9133164B2
(en)
|
2011-04-13 |
2015-09-15 |
Innov88 Llc |
MIF inhibitors and their uses
|
|
WO2012162635A1
(en)
|
2011-05-26 |
2012-11-29 |
Sunovion Pharmaceuticals Inc. |
Metabotropic glutamate receptors 5 modulators and methods of use thereof
|
|
US8815909B2
(en)
|
2011-07-18 |
2014-08-26 |
Bristol-Myers Squibb Company |
Diaminocyclohexane compounds and uses thereof
|
|
JP5741850B2
(ja)
|
2011-09-13 |
2015-07-01 |
コニカミノルタ株式会社 |
光学フィルム、それを含む偏光板および液晶表示装置
|
|
US10028926B2
(en)
|
2012-01-06 |
2018-07-24 |
Gemphire Therapeutics Inc. |
Methods of reducing risk of cardiovascular disease
|
|
TW201348231A
(zh)
|
2012-02-29 |
2013-12-01 |
Amgen Inc |
雜雙環化合物
|
|
WO2013134047A2
(en)
|
2012-03-07 |
2013-09-12 |
The Mclean Hospital Corporation |
Aminoquinoline derivatives and uses thereof
|
|
JPWO2013137371A1
(ja)
|
2012-03-15 |
2015-08-03 |
興和株式会社 |
新規ピリミジン化合物及びそれらを含有する医薬
|
|
WO2013158939A1
(en)
|
2012-04-18 |
2013-10-24 |
Hemoshear, Llc |
In vitro model for pathological or physiologic conditions
|
|
US9255154B2
(en)
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
|
CA2874244A1
(en)
|
2012-05-25 |
2013-11-28 |
Catabasis Pharmaceuticals, Inc. |
Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9)
|
|
US9434695B2
(en)
|
2012-07-18 |
2016-09-06 |
Sunshine Lake Pharma Co., Ltd |
Nitrogenous heterocyclic derivatives and their application in drugs
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
AR092924A1
(es)
|
2012-10-09 |
2015-05-06 |
Sanofi Sa |
Derivados de pirrolidinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
|
|
HK1211232A1
(en)
|
2012-12-21 |
2016-05-20 |
Sanofi |
Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
|
|
TWI644899B
(zh)
|
2013-02-04 |
2018-12-21 |
健生藥品公司 |
Ｆｌａｐ調節劑
|
|
AU2014211727B2
(en)
|
2013-02-04 |
2018-07-26 |
Prexton Therapeutics Sa |
Positive allosteric modulators of mGluR3
|
|
SI3527563T1
(sl)
|
2013-03-12 |
2022-01-31 |
Vertex Pharmaceuticals Incorporated |
Inhibitorji DNA-PK
|
|
MX2015014666A
(es)
|
2013-04-17 |
2016-03-01 |
Pfizer |
Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares.
|
|
TWI682780B
(zh)
|
2013-05-30 |
2020-01-21 |
美商再生元醫藥公司 |
醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
|
|
TW202021614A
(zh)
|
2013-06-07 |
2020-06-16 |
法商賽諾菲生物技術公司 |
藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
|
|
WO2014201173A1
(en)
|
2013-06-12 |
2014-12-18 |
Amgen Inc. |
Bicyclic sulfonamide compounds as sodium channel inhibitors
|
|
AR092240A1
(es)
|
2013-08-26 |
2015-04-08 |
Sunshine Lake Pharma Co Ltd |
Derivados heterociclicos nitrogenados y su aplicacion en farmacos
|
|
CN105658232A
(zh)
|
2013-08-30 |
2016-06-08 |
阿尔莫生物科技股份有限公司 |
使用白细胞介素-10治疗疾病和病症的方法
|
|
KR20220048051A
(ko)
|
2013-10-11 |
2022-04-19 |
사노피 바이오테크놀로지 |
고지혈증을 치료하기 위한 ｐｃｓｋ9 억제제의 용도
|
|
CN104558685B
(zh)
|
2013-10-24 |
2017-09-29 |
中国石油化工股份有限公司 |
一种磷氮膨胀型阻燃剂及其合成方法
|
|
JP2017019724A
(ja)
|
2013-10-25 |
2017-01-26 |
第一三共株式会社 |
置換ピリジン化合物および他の医薬の組み合わせ
|
|
EP3080148A2
(en)
|
2013-12-11 |
2016-10-19 |
Glycotope GmbH |
Glycosylated glycophorin peptides
|
|
WO2015086732A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues
|
|
EP3080152A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
|
EP3080155A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
|
|
WO2015086733A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
|
TW201609799A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
雙重ｇｌｐ－１／ｇｉｐ受體促效劑
|
|
WO2015086728A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
|
LT3119757T
(lt)
|
2014-03-17 |
2018-07-10 |
Pfizer Inc. |
Diacilglicerolio aciltransferazės 2 inhibitoriai, skirti panaudoti metabolinių ir susijusių ligų gydyme
|
|
AR099936A1
(es)
|
2014-04-04 |
2016-08-31 |
Sanofi Sa |
Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
|
|
AR099937A1
(es)
|
2014-04-04 |
2016-08-31 |
Sanofi Sa |
Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
|
|
EP3126346B1
(en)
|
2014-04-04 |
2018-07-11 |
Sanofi |
Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
EP3148537B1
(en)
|
2014-05-30 |
2018-09-26 |
Université Paris Descartes |
Cyclic compounds having a 1,3 diamino-functionality for use in the treatment of hiv infection
|
|
WO2015187295A2
(en)
|
2014-06-02 |
2015-12-10 |
Armo Biosciences, Inc. |
Methods of lowering serum cholesterol
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
TWI677489B
(zh)
|
2014-06-20 |
2019-11-21 |
美商基利科學股份有限公司 |
多環型胺甲醯基吡啶酮化合物之合成
|
|
RU2723018C2
(ru)
|
2014-07-16 |
2020-06-08 |
Санофи Байотекнолоджи |
Способы лечения пациентов с высоким риском возникновения сердечно-сосудистых заболеваний, имеющих гиперхолестеринемию
|
|
ES2826443T3
(es)
|
2014-09-25 |
2021-05-18 |
Araxes Pharma Llc |
Inhibidores de proteínas mutantes KRAS G12C
|
|
US10245254B2
(en)
|
2014-10-03 |
2019-04-02 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Glutaminase inhibitors
|
|
BR112017015273A2
(pt)
|
2015-01-20 |
2018-01-09 |
Merial Inc. |
compostos e composições antihelmínticos e método de utilizações dos mesmos
|
|
WO2016127102A2
(en)
|
2015-02-06 |
2016-08-11 |
Ernesto Abel-Santos |
Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis
|
|
AR103954A1
(es)
|
2015-03-18 |
2017-06-14 |
Zealand Pharma As |
Análogos de amilina
|
|
EP3973958A3
(en)
|
2015-03-20 |
2022-06-22 |
Aarhus Universitet |
Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders
|
|
US10336802B2
(en)
|
2015-04-16 |
2019-07-02 |
Zealand Pharma A/S |
Acylated glucagon analogue
|
|
AU2016348638A1
(en)
|
2015-11-06 |
2018-06-07 |
Gemphire Therapeutics Inc. |
Gemcabene combinations for the treatment of cardiovascular disease
|
|
TW201731867A
(zh)
|
2015-12-02 |
2017-09-16 |
賽諾菲公司 |
Ｆｇｆ２１變異體
|
|
IL303850A
(en)
|
2015-12-11 |
2023-08-01 |
Univ Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
|
WO2017125506A1
(en)
|
2016-01-20 |
2017-07-27 |
Janssen Sciences Ireland Uc |
Aryl substituted pyrimidines for use in influenza virus infection
|
|
CN108697677A
(zh)
|
2016-02-26 |
2018-10-23 |
燿石治疗公司 |
对正接受降脂疗法的纯合型家族性高胆固醇血症患者的治疗
|
|
CN109152784B
(zh)
|
2016-03-16 |
2021-12-28 |
库拉肿瘤学公司 |
经取代的menin-mll抑制剂及使用方法
|
|
JP2019513802A
(ja)
|
2016-04-14 |
2019-05-30 |
ルシー マイケル |
組み合わせ組成物およびその使用方法
|
|
TW201808888A
(zh)
|
2016-05-05 |
2018-03-16 |
嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
|
AU2017292184A1
(en)
|
2016-07-08 |
2019-02-07 |
Staten Biotechnology B.V. |
Anti-Apoc3 antibodies and methods of use thereof
|
|
JP2019532049A
(ja)
|
2016-09-15 |
2019-11-07 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． |
Ｄｒｐ１阻害を通じたｐｃｓｋ９およびｌｄｌｒのモジュレーション法
|
|
LT3529360T
(lt)
|
2016-10-18 |
2024-07-25 |
Novartis Ag |
Metodai, skirti širdies ir kraujagyslių ligų prevencijai mažinant proproteinų konvertazės subtilizino keksino 9 (pcsk9) baltymo kiekį
|
|
SG11201903945XA
(en)
|
2016-11-10 |
2019-05-30 |
Csl Ltd |
Reconstituted high density lipoprotein treatment of myocardial infarction
|
|
JOP20190112A1
(ar)
|
2016-11-14 |
2019-05-14 |
Amgen Inc |
علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
|
|
WO2018106820A1
(en)
|
2016-12-07 |
2018-06-14 |
Kura Oncology, Inc. |
Methods of promoting beta cell proliferation
|
|
WO2018106818A1
(en)
|
2016-12-07 |
2018-06-14 |
Kura Oncology, Inc. |
Methods of promoting beta cell proliferation
|
|
CN110267964B
(zh)
|
2016-12-13 |
2022-05-03 |
百时美施贵宝公司 |
作为IL-12、IL-23及/或IFNα响应调节剂的经取代的杂芳基氧化膦化合物
|
|
EP3579782B1
(en)
|
2017-02-08 |
2024-05-01 |
Brooke Schumm |
Intra-operative radiation therapy capsule with cylindrical shell radiation containment shutter system
|
|
CN110637027B
(zh)
|
2017-02-08 |
2024-08-30 |
百时美施贵宝公司 |
包含药代动力学增强子的修饰的松弛素多肽及其用途
|
|
AR110988A1
(es)
|
2017-02-21 |
2019-05-22 |
Sanofi Sa |
Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados
|
|
WO2018165718A1
(en)
|
2017-03-17 |
2018-09-20 |
Cardio Therapeutics Pty Ltd |
Heterocyclic inhibitors of pcsk9
|
|
CN110691779B
(zh)
|
2017-03-24 |
2023-10-10 |
库拉肿瘤学公司 |
治疗血液系统恶性肿瘤和尤因肉瘤的方法
|
|
JP2020517242A
(ja)
|
2017-04-21 |
2020-06-18 |
スターテン・バイオテクノロジー・ベー・フェー |
抗ＡｐｏＣ３抗体およびその使用方法
|
|
IL271149B2
(en)
|
2017-06-14 |
2024-05-01 |
Trevena Inc |
Compounds for modulating s1p1 activity and methods of using the same
|
|
WO2019001379A1
(zh)
|
2017-06-26 |
2019-01-03 |
深圳市塔吉瑞生物医药有限公司 |
用于抑制激酶活性的吲唑类化合物及其组合物及应用
|
|
CN109384712B
(zh)
|
2017-08-14 |
2021-05-07 |
北京宽厚医药科技有限公司 |
靶向nk1受体拮抗剂及其在化疗所致恶心、呕吐治疗中的应用
|
|
WO2019079701A1
(en)
|
2017-10-20 |
2019-04-25 |
Dana-Farber Cancer Institute, Inc. |
HETEROBIFUNCTIONAL COMPOUNDS HAVING IMPROVED SPECIFICITY FOR BRD4 BROMODOMAINE
|
|
EP3687538B1
(en)
|
2017-10-30 |
2024-04-17 |
Montreal Heart Institute |
Methods of treating elevated plasma cholesterol
|
|
KR20200074975A
(ko)
|
2017-10-31 |
2020-06-25 |
스태튼 바이오테크놀로지 비.브이. |
항-ApoC3 항체 및 이의 사용 방법
|
|
UY37957A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
|
MX2020005210A
(es)
|
2017-11-21 |
2020-08-20 |
Bristol Myers Squibb Co |
Compuestos de heteroarilo sustituidos con alquilamida de piridinsulfona.
|
|
WO2019111225A1
(en)
|
2017-12-08 |
2019-06-13 |
Avaliv Therapeutics |
Compounds and methods for the treatment of non‑alcoholic steatohepatitis
|
|
WO2019126071A1
(en)
|
2017-12-18 |
2019-06-27 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
|
|
CA3088788A1
(en)
|
2018-01-17 |
2019-07-25 |
Vertex Pharmaceuticals Incorporated |
Dna-pk inhibitors
|
|
US11513131B2
(en)
|
2018-01-22 |
2022-11-29 |
Global Genomics Group, LLC |
Low density lipoprotein triglycerides (LDL-TG) as a biomarker of cardiovascular disease and uses thereof
|
|
JP2021512051A
(ja)
|
2018-01-23 |
2021-05-13 |
ギラ セラピューティクス インコーポレイテッドＧｉｌａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
ペプチドｙｙ薬学的調剤物、組成物、および方法
|
|
JP2021517141A
(ja)
|
2018-03-09 |
2021-07-15 |
ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド |
心血管疾患のための組み合わせ治療
|
|
EP3768667B1
(en)
|
2018-03-22 |
2023-04-12 |
Bristol-Myers Squibb Company |
Heterocyclic compounds comprising pyridine useful as modulators of il-12, il-23 and/or ifn alpha responses
|
|
CN110384801B
(zh)
|
2018-04-20 |
2021-09-14 |
中国科学院上海药物研究所 |
miRNA552簇的微小RNA在治疗LDLC相关代谢性疾病中的应用
|
|
ES2969982T3
(es)
|
2018-04-24 |
2024-05-23 |
Vertex Pharma |
Compuestos de pteridinona y usos de los mismos
|
|
US20190374526A1
(en)
|
2018-06-06 |
2019-12-12 |
Merck Sharp & Dohme Corp. |
Substituted Heterocyclic Compounds as Inhibitors of PRDM9
|
|
US11442072B2
(en)
|
2018-07-10 |
2022-09-13 |
Jenny and Antti Wihuri Foundation |
Method for measuring LDL aggregation
|
|
CR20210110A
(es)
|
2018-08-31 |
2021-05-13 |
Pfizer |
Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas
|
|
WO2020070678A2
(en)
|
2018-10-03 |
2020-04-09 |
Staten Biotechnology B.V. |
Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
|
|
AU2019364336B2
(en)
|
2018-10-22 |
2023-11-16 |
Alumis Inc. |
TYK2 inhibitors and uses thereof
|
|
CN113286885A
(zh)
|
2018-11-09 |
2021-08-20 |
诺华股份有限公司 |
用靶向apo(a)的经缀合的反义化合物降低心血管事件的风险的方法
|
|
CA3122035A1
(en)
|
2018-12-06 |
2020-06-11 |
Zora Biosciences Oy |
Biomarkers for cardiovascular events
|
|
AU2020209216A1
(en)
*
|
2019-01-18 |
2021-08-26 |
Astrazeneca Ab |
PCSK9 inhibitors and methods of use thereof
|
|
SG11202107614PA
(en)
*
|
2019-01-18 |
2021-08-30 |
Astrazeneca Ab |
Pcsk9 inhibitors and methods of use thereof
|
|
CN111484480B
(zh)
|
2019-01-29 |
2023-08-11 |
上海翰森生物医药科技有限公司 |
一种多环类衍生物抑制剂、其制备方法和应用
|
|
WO2020160518A1
(en)
|
2019-02-01 |
2020-08-06 |
Memorial Sloan Kettering Cancer Center |
Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker
|
|
WO2020214753A1
(en)
|
2019-04-17 |
2020-10-22 |
Ngm Biopharmaceuticals, Inc. |
Combination therapy for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
WO2020234726A1
(en)
|
2019-05-20 |
2020-11-26 |
Pfizer Inc. |
Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
|
|
JP2023506732A
(ja)
|
2019-12-10 |
2023-02-20 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ホモ接合型家族性高コレステロール血症を処置するためのｐｃｓｋ９阻害剤の使用
|
|
WO2021209808A1
(en)
|
2020-04-16 |
2021-10-21 |
Abionyx Pharma Sa |
Cer-001 therapy for treating kidney disease
|
|
CN113713107B
(zh)
|
2020-05-26 |
2022-09-23 |
中国科学院上海药物研究所 |
miRNA552簇的微小RNA在治疗糖脂代谢病中的应用
|
|
CA3179316A1
(en)
|
2020-05-29 |
2021-12-02 |
Andrew W. HAMER |
Pcsk9 inhibitors and methods of use thereof to treat cholesterol-related disorders
|
|
TWI897977B
(zh)
|
2020-06-10 |
2025-09-21 |
荷蘭商菲林公司 |
用於治療動脈粥樣硬化性心血管疾病之藥物化合物
|
|
WO2022028317A1
(en)
|
2020-08-05 |
2022-02-10 |
Rezubio Pharmaceuticals Co., Ltd |
Antidiabetic compounds and compositions
|
|
WO2022029334A1
(en)
|
2020-08-07 |
2022-02-10 |
Gbiotech S.À.R.L. |
Combination therapies for treating coronavirus infection
|
|
WO2022040371A1
(en)
|
2020-08-19 |
2022-02-24 |
Biogen Ma Inc. |
Methods for treating hypercholesterolemia
|
|
JP2023543409A
(ja)
|
2020-09-15 |
2023-10-16 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
疼痛に対するｌｅｐｒアゴニストの使用
|
|
PL4232448T3
(pl)
|
2020-10-20 |
2025-10-13 |
Halo Therapeutics Ltd |
Agoniści receptora 1 wolnych kwasów tłuszczowych i ich zastosowanie w chorobach związanych z wymienionym receptorem
|
|
WO2022098841A1
(en)
|
2020-11-05 |
2022-05-12 |
Amgen Inc. |
METHODS FOR TREATING ATHEROSCLEROTIC CARDIOVASCULAR DISEASE WITH LPA-TARGETED RNAi CONSTRUCTS
|
|
US12419888B2
(en)
|
2020-12-11 |
2025-09-23 |
Institut De Cardiologie De Montreal |
Methods of treating elevated plasma cholesterol
|
|
WO2022123120A1
(en)
|
2020-12-11 |
2022-06-16 |
Helsingin Yliopisto |
Method for determining a likelihood of a subject to respond to lipid lowering therapy
|
|
PL4294257T3
(pl)
|
2021-02-22 |
2026-02-09 |
Regeneron Pharmaceuticals, Inc. |
Sposób diagnozowania i leczenia częściowej lipodystrofii
|
|
WO2022182918A1
(en)
|
2021-02-25 |
2022-09-01 |
Icahn School Of Medicine At Mount Sinai |
Methods for inhibiting inflammation and progression of atherosclerotic plaques and cardiovascular events in patients with cerebro- and cardio-vascular disease
|
|
EP4312978A2
(en)
|
2021-03-27 |
2024-02-07 |
TRX Biosciences Limited |
Compositions having improved bioavailability of therapeutics
|
|
AU2022299514A1
(en)
|
2021-06-24 |
2024-01-18 |
Sirnaomics, Inc. |
Products and compositions
|
|
EP4359441A1
(en)
|
2021-06-25 |
2024-05-01 |
Amgen Inc. |
Treatment of cardiovascular disease with trem-1 antigen binding proteins
|
|
WO2023285583A1
(en)
|
2021-07-14 |
2023-01-19 |
Eternygen Uk Ltd. |
5,6,7,8-tetrahydro-2,6- and 2,7-naphthyridine derivatives for use in the treatment of diseases responsive to citrate transporter modulation
|
|
WO2023052783A1
(en)
|
2021-09-30 |
2023-04-06 |
Sitryx Therapeutics Limited |
Novel compounds
|
|
WO2023079294A1
(en)
|
2021-11-05 |
2023-05-11 |
Sitryx Therapeutics Limited |
Phthalazine derivatives as pyruvate kinase modulators
|
|
EP4446307A4
(en)
|
2021-11-12 |
2025-12-10 |
Shenzhen Jingtai Tech Co Ltd |
ASPARTIC ACID DERIVATIVE AND ITS USE IN THE TREATMENT OF METABOLIC DISEASES SUCH AS HEPATIC FIBROSIS AND NON-ALCOHOLIC HEPATITIS
|
|
CN114277032A
(zh)
|
2021-12-31 |
2022-04-05 |
华中科技大学同济医学院附属协和医院 |
一种低密度脂蛋白受体基因突变体及其应用
|
|
US20250223281A1
(en)
|
2022-01-14 |
2025-07-10 |
Rezubio Pharmaceuticals Co., Ltd |
Antidiabetic compounds and compositions
|
|
TW202345865A
(zh)
|
2022-01-24 |
2023-12-01 |
大陸商上海舶望製藥有限公司 |
抑制LPA(Apo(a))蛋白表達的組合物和方法
|
|
CN116617390A
(zh)
|
2022-02-11 |
2023-08-22 |
武汉大学 |
Asgr1抑制剂在促进胆固醇外排和治疗非酒精性脂肪性肝病中的应用
|
|
US20250177377A1
(en)
|
2022-03-11 |
2025-06-05 |
University Of Florida Research Foundation, Incorporated |
Targeting ptchd1 and neuronal cholesterol to enhance safety of opioid analgesics
|
|
US20230338419A1
(en)
|
2022-03-21 |
2023-10-26 |
The Trustees Of The University Of Pennsylvania |
Methods and apparatus for diagnosis and detection of cardiac allograft vasculopathy
|
|
CN119161484A
(zh)
|
2022-04-25 |
2024-12-20 |
武汉大学 |
抗asgr1单克隆抗体及其应用
|
|
US20250295724A1
(en)
|
2022-05-13 |
2025-09-25 |
Zhejiang Yangshengtang Institute Of Natural Medication Co., Ltd. |
Composition of malus niedzwetzkyana dieck and prunus cerasifera ehrhart and use thereof in terms of resisting atherosclerosis
|
|
CN115581694A
(zh)
|
2022-11-10 |
2023-01-10 |
正大青春宝药业有限公司 |
洋川芎内脂i在制备治疗高血脂症药物中的应用
|
|
CN117180404A
(zh)
|
2023-10-24 |
2023-12-08 |
清华大学 |
Cholesin在调节胆固醇稳态中的用途
|
|
CN117482076A
(zh)
|
2023-11-24 |
2024-02-02 |
中国人民解放军陆军军医大学第二附属医院 |
甲硫氨酸类化合物在制备pcsk9抑制剂中的应用
|